The Scott M. Hammer Annual Update on HIV Management in New York, New York

Last Modified: Mar 28, 2024 @ 4:30 PM

Program Description

Join us for the highly anticipated and dynamic IAS–USA annual course in New York, New York, for the most current and clinically relevant information in HIV care. Don’t miss out on the opportunity to engage with faculty and peers in person and to stay at the forefront of what’s new in HIV management. This live course will be in person at the NYU Skirball Center, and there will NOT be a simultaneous virtual component for this course.

This in-person course will focus on recent advances in HIV medicine, including updates from Conference on Retroviruses and Opportunistic Infections (CROI) 2024; new antiretroviral formulations and strategies, management of substance use disorder (SUD) in people with HIV; sexually transmitted infections (STIs) prevention, including current epidemiology in the US; update in the treatment implications of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) trial in people with HIV; review of the current state and understanding of long-acting drugs for the treatment and prevention of HIV; challenges of hypertension and cardiometabolic complications associated with antiretroviral therapy; and a case-based panel discussion on antiretroviral therapy. This course will also highlight the emerging data around the use of glucagon-like peptide 1 (GLP-1) agonists drugs among individuals with HIV, including diabetes, weight loss, potential treatment for addictions, comorbidities, and explore other ongoing research on their use.

We remain committed to closely monitoring the evolving state of the pandemic. We will ensure that our vaccination policy and mask guidelines align with the circumstances leading up to the course.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

• Implement the latest recommendations for initiating and changing antiretroviral therapy in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
• Describe the most current data from recent HIV scientific conferences, including research on new and investigational antiretroviral drugs
• Describe the current epidemiology, clinical presentation, prevention, and management of relevant common sexually transmitted infections (STIs) in adults with HIV
• Manage substance use disorders, including opioids, stimulants, and alcohol in people with HIV
• Integrate findings from the REPRIEVE trial into the treatment plans for adults with HIV
• Describe the current research of GLP-1 agonist therapy for people with HIV
• Identify the challenges of hypertension and cardiometabolic complications in people on antiretroviral therapy

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection
• Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 14 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.